Cancer Research
Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting, being held April 8 – 13, 2022 in New Orleans, Louisiana. “Cancer research is an important focus area for Agilent. The AACR…
Read More
Excerpt from the Press Release: SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced it is advancing its second TCR-T program, TK-2504, toward the clinic and presented preclinical data on its ability to generate novel TCRs targeting the KRASG12V antigen. The…
Read More
The study reveals replication stress in ecDNA enabled cancers as a unique vulnerability and therapeutic strategy for treating gene amplified cancers Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present a new finding at the American…
Read More
ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to ~9 months from historical data with KEYTRUDA® alone Median overall survival of 33.7…
Read More
Pilot aims to prevent symptoms in advance with contextualized data for cancer patient care Excerpt from the Press Release: (Carevive), the leading oncology-focused health technology company centered on understanding and improving the cancer patient experience, announced today a partnership with Blue Spark Technologies, a leader and an innovator in wearable wireless medical device solution The study…
Read More
Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type. BriaCell and National Cancer Institute collaborating on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BriaCell to present Bria-OTS™ approach at the American Association for Cancer Research (AACR) Annual Meeting 2022. Excerpt from the…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., March 30, 2022 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa’s therapy…
Read More
Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without increased side effects Excluding patients (i) who had not responded to even their first treatment with a platinum-based therapy (“primary platinum-refractory” patients) or (ii) who had received four or more prior lines of therapy,…
Read More
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent cohorts Initial safety and pharmacokinetics data from study expected in the second half of 2022 Excerpt from the Press Release: SAN DIEGO, March 31, 2022 (GLOBE…
Read More
Independent review identified, no safety concerns in trial’s final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients Multi-indication trial being conducted in collaboration with Roche and AIO also includes pancreatic and advanced anal cancer cohorts Excerpt from the Press Release:…
Read More